Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Track MGRX with free AI briefings, catalyst countdowns, and dilution alerts.

MGRX · MANGOCEUTICALS, INC.

Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.

$228,688 Cash on Hand
0.9mo Cash Runway
8.5% Short Interest
Follow MGRX by email Get an email when MGRX reports key news in an SEC filing, pushes back a promised milestone, files for a stock offering, lands on the Downside Radar or has an FDA decision. Free, no account needed.

We send one confirmation email first. Only emails about MGRX, unsubscribe in one click. Privacy

📄 Latest SEC Filings in Plain English

Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.

💰 Cash Runway & Dilution Risk

MGRX holds $228,688 in cash and short-term investments (as of Jun 30, 2026) and burns about $785,925/quarter from operations, an estimated runway of 0.9 months at that rate (BioRadar estimate, not company guidance).

Dilution pressure: 90 · High

Recent financing filings on SEC EDGAR:

Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when MGRX files for a raise →

👥 Who Owns MGRX

Insiders 6.5% Institutions 11.3% Public and other holders 82.2%
HolderTypeShares% of sharesAs of
Armistice Capital, LLC Institution (13F) 1,536,000 6.91% 2025-12-31
Jacob D. Cohen
Chief Executive Officer, Director, 10% o · +3.43M options
Insider 605,000 2.72% 2026-03-16
Vanguard Group Inc Institution (13F) 489,532 2.20% 2025-12-31
Eugene M Johnston
CFO
Insider 220,000 0.99% 2026-07-28
Amanda Elizabeth Hammer
Chief Operating Officer
Insider 175,000 0.79% 2024-06-03
Ikarian Capital, LLC Institution (13F) 138,146 0.62% 2025-12-31
Lorraine Pamela D'Alessio
Director
Insider 136,667 0.61% 2025-09-09
Kenny Myers
Director
Insider 136,667 0.61% 2025-09-09
Geode Capital Management, LLC Institution (13F) 108,322 0.49% 2025-12-31
Alex P. Hamilton
Director
Insider 101,667 0.46% 2026-07-28
Antonios Isaac
President, Director
Insider 60,000 0.27% 2025-04-10
Jane Street Group, LLC Institution (13F) 47,503 0.21% 2025-12-31

Share count 22,224,420 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the largest 13F holders (13F quarter ending 2025-12-31). Sources have different dates, so the split is approximate. Source: SEC EDGAR.

📈 Recent Insider Activity (Form 4)

Trade dateInsiderTransactionSharesPriceOwned after
2026-03-16
filed 2026-03-20
Cohen Jacob D.
Option award (A) 2,000,000 – –
2026-03-16
filed 2026-03-20
Cohen Jacob D.
Returned to issuer (D) 2,000,000 – –
2026-03-16
filed 2026-03-20
Cohen Jacob D.
Option award (A) 83,333 – –
2026-03-16
filed 2026-03-20
Cohen Jacob D.
Returned to issuer (D) 83,333 – –
2026-03-16
filed 2026-03-20
Cohen Jacob D.
Option award (A) 50,000 – –

Only open-market purchases (P) and sales (S) are trading decisions. Awards (A), option exercises (M) and tax withholding (F) are compensation mechanics. Source: SEC Form 4.

Get the full MGRX picture

The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for MGRX and every other ticker you follow. Card required, cancel anytime.

Start 7-day free trial →

Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.